Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 in participants with advancedat a late stage, far along solid tumors.
Intervention / Treatment
- Drug: BG-C137
Inclusion Criteria:
- Histologically or cytologically confirmed advanced or metastatic solid tumors.
- Life expectancy of ≥ 3 months.
- Prior standard systemic therapy in the advanced or metastatic setting. Dosethe amount of medication taken Escalation: Participants for whom further standard treatment is not available, not tolerated or determined not appropriate based on the investigator’s judgment. Safety Expansion and Dose Expansion: Participants who have received 1 or 2 prior lines of systemic therapy in the advanced or metastatic setting.
- Participants must provide agreement for collection of archival tissuea group of cells that work together to perform a function or recently obtained fresh tumor biopsyremoval of a section of tissue to analyse for cancer cells for central evaluation of FGFR2b expression levels and other biomarker assessments.
- ≥ 1 measurable lesion per RECIST v1.1.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) Performance Status of 0 or 1.
- Adequate organ function as determined per protocol.